Tanning Peptides: How They Work, Risks, and What to Know

Key Takeaways

• What they are: Synthetic analogs of alpha-melanocyte-stimulating hormone (alpha-MSH) that activate the MC1R receptor to stimulate melanin synthesis, producing skin darkening without UV exposure.
• Regulatory status: As of April 2026, melanotan II is not FDA-approved for any indication. Afamelanotide (melanotan I) is FDA-approved as Scenesse for erythropoietic protoporphyria only — not for cosmetic tanning. Grey-market tanning peptide products are sold outside FDA oversight.
• Evidence stage: Human pharmacology data from Phase I clinical studies confirms skin pigmentation effect. Case reports associate use with melanoma. No completed safety or efficacy trials for cosmetic tanning use exist. Evidence for harm is documented; evidence for safe cosmetic use is not established.
• Primary concern: Melanocytic changes including new nevi, changes in existing moles, and melanoma case reports represent documented clinical safety concerns. Grey-market products carry additional contamination and dosing uncertainty risks.

What Tanning Peptides Are

Tanning peptides are synthetic analogs of alpha-melanocyte-stimulating hormone (alpha-MSH), an endogenous neuropeptide that binds the melanocortin 1 receptor (MC1R) to regulate skin pigmentation as part of the body's natural UV-response system. Slominski and colleagues' foundational 2004 review in Physiological Reviews described the melanin pigmentation system and its hormonal regulation, establishing that endogenous alpha-MSH is released in response to UV exposure and drives eumelanin synthesis through MC1R. Synthetic tanning peptides replicate this molecular signal without requiring UV exposure.

The two primary compounds are melanotan I (afamelanotide) and melanotan II (MT-II). They are structurally distinct, with different receptor selectivities and different regulatory histories. Afamelanotide became the FDA-approved drug Scenesse for erythropoietic protoporphyria — a rare photosensitivity condition. Melanotan II, a less selective MC1R agonist, has no approved indication anywhere. The grey-market tanning products circulating online are primarily melanotan II, though products labeled as melanotan I also circulate.

Discovery and Background

Alpha-MSH research began in endocrinology, not cosmetics. The natural peptide's role in pigmentation, appetite regulation, and the stress response was established over decades of academic endocrinology research before synthetic analogs attracted attention. The MC1R mechanism described by Lin and Fisher in a landmark 2007 Nature review established the melanocyte biology and skin pigmentation signaling axis that tanning peptides exploit. University of Arizona researchers, investigating photoprotection strategies in the late 1980s and 1990s, developed synthetic alpha-MSH analogs with the aim of inducing protective melanin production in UV-sensitive individuals. Afamelanotide — their most clinically developed compound — ultimately reached approval not for cosmetics but for erythropoietic protoporphyria. The grey-market tanning products that followed are more closely related to the early analogs than to the FDA-reviewed therapeutic compound.

The melanocortin system extends well beyond pigmentation. Herraiz and colleagues, in a 2021 review in Pigment Cell and Melanoma Research, reviewed MC1R's pleiotropic effects beyond pigmentation, including UV protection mechanisms, DNA repair signaling, and melanoma risk modulation. This broader biology is relevant to understanding why systemic MC1R agonism — as opposed to local UV-driven activation — carries effects beyond skin color.

How Tanning Peptides Work in the Body

The mechanism of tanning peptides operates through the MC1R receptor on melanocytes, triggering a cascade that shifts melanin production toward eumelanin — the brown-black pigment responsible for visible tanning. This mechanism is well-characterized at the molecular level, though its systemic consequences in humans are less thoroughly studied.

MC1R activation and eumelanin synthesis

Alpha-MSH and its synthetic analogs bind MC1R on the surface of melanocytes, activating adenylyl cyclase through a Gs-coupled mechanism, which increases intracellular cyclic AMP. Elevated cAMP activates MITF (microphthalmia-associated transcription factor), upregulating tyrosinase and other enzymes in the melanogenesis pathway. This shifts melanin production from pheomelanin (reddish-yellow) toward eumelanin (brown-black), producing visible skin darkening. The mechanism works at the cellular level — this is documented biology, not marketing.

Receptor selectivity and systemic effects

The distinction between melanotan I (afamelanotide) and melanotan II is pharmacologically significant. Melanotan II activates not only MC1R but also MC3R and MC4R — receptors involved in appetite regulation, autonomic nervous system function, and sexual arousal. MC4R activation produces spontaneous erections (a documented adverse effect of MT-II) and contributes to nausea. Melanotan I is more selective for MC1R, explaining why afamelanotide's safety profile in erythropoietic protoporphyria trials was manageable. Grey-market MT-II products, with their broader receptor profile, carry more unpredictable systemic effects. The original Phase I human study of MT-II published in Life Sciences in 1996 demonstrated tanning activity at subcutaneous doses alongside the systemic effects that follow from off-target receptor engagement.

Melanocyte proliferation risk

Beyond tanning, MC1R activation stimulates melanocyte proliferation. Abdel-Malek and colleagues, writing in the Proceedings of the National Academy of Sciences in 1995, demonstrated that melanotropic peptides produce mitogenic and melanogenic stimulation of normal human melanocytes in vitro — cell-level evidence that exogenous MC1R agonists can drive unwanted melanocyte proliferation beyond pigmentation. Cell-level mitogenicity is the proposed mechanistic basis for clinical observations of new nevi formation following melanotan use and for case reports of malignant change in susceptible individuals — a plausibility argument, not a direct causal demonstration in humans. A 2009 case report in the Archives of Dermatology (now JAMA Dermatology) documented alpha-MSH-induced eruptive nevi following synthetic alpha-MSH peptide use, showing that melanocytic proliferation in predisposed individuals can be clinically significant.

What the Research Shows

As of April 2026, no completed Phase 3 safety or efficacy trials for cosmetic tanning use of melanotan I or II exist. The evidence base consists of Phase I human pharmacology studies from the 1990s, case reports documenting adverse effects, systematic reviews of safety signals, and cell biology establishing the proliferation mechanism. This evidence landscape is unusually clear in one direction: effects on pigmentation are documented, and safety concerns are documented.

Human pharmacology (Phase I studies)

The original Phase I clinical study of melanotan II in humans, published in Life Sciences in 1996, confirmed that subcutaneous MT-II at low doses produced skin pigmentation in light-skinned subjects [human study]. A 1997 pharmacokinetic study of afamelanotide in Biopharmaceutics & Drug Disposition documented dose-dependent skin pigmentation and characterized the pharmacokinetics of the melanotan I variant [human study]. These studies establish biological efficacy — these compounds do produce pigmentation. The 1996 Phase I MT-II study also documented short-term adverse effects observed even in controlled clinical settings, including nausea, spontaneous erections, and facial flushing — the spontaneous erections being specific to the less MC1R-selective MT-II, not the MT-I variant.

Safety signals: nevi and melanoma case reports

A 2013 case report in the Irish Medical Journal documented atypical melanocytic nevi — new and changing moles — following melanotan injection [case report]. A 2012 case report in the Australasian Journal of Dermatology associated melanotan use with melanoma in situ in a patient with dysplastic nevi [case report]. A 2014 case report in Dermatology documented melanoma associated with melanotan-II use [case report]. Multiple independent case reports associating the same compound with the same adverse outcome are a signal that warrants serious consideration, even without a completed controlled trial.

Systematic review findings

The most authoritative safety summary is Habbema and colleagues' 2017 narrative review in the International Journal of Dermatology, documenting melanocytic changes, new nevi, changes in existing moles, and systemic side effects from unregulated use of alpha-MSH analogs [review]. A 2021 qualitative study in Dermatology documented melanotan II user experiences, motivations, dosing practices, and self-reported side effects from online forums, providing real-world population-level context [human observational].

Evidence-level summary

• In vitro (cell culture)
  • Volume of evidence: Extensive
  • Key finding: Alpha-MSH stimulates melanocyte proliferation and melanogenesis; MC1R activation drives eumelanin synthesis
  • Strength of inference: Establishes mechanism; supports both the tanning effect and the proliferation risk
• Animal models
  • Volume of evidence: Moderate
  • Key finding: Alpha-MSH analogs increase melanocyte proliferation and can promote melanocytic lesions in predisposed models
  • Strength of inference: Supports mechanism; does not define human risk magnitude
• Human Phase I studies
  • Volume of evidence: Limited (1990s era)
  • Key finding: Skin pigmentation confirmed; systemic adverse effects (nausea, erections, hypotension) documented in controlled settings
  • Strength of inference: Establishes pharmacological activity and short-term adverse event profile; long-term safety not characterized
• Case reports and case series
  • Volume of evidence: Multiple independent publications
  • Key finding: New and changing nevi; melanoma in situ; melanoma; systemic toxicity
  • Strength of inference: Documents real-world safety signals; does not establish causation; consistent pattern across independent reports

How Grey-Market Tanning Peptides Are Marketed and Sourced

Grey-market tanning peptides are sold as injectable and intranasal products outside pharmaceutical-grade manufacturing oversight. The pharmacological basis for transmucosal absorption at cosmetic-relevant doses has not been clearly established in peer-reviewed pharmacokinetic literature. The absence of pharmaceutical-grade manufacturing oversight for grey-market products compounds the safety concerns associated with the compounds themselves.

Grey-market injectable products: no legal pathway exists

Grey-market MT-II products are typically injected subcutaneously. A 2015 study in Drug Testing and Analysis identified melanotan II products sold online with inconsistent composition and unlabeled ingredients. Contamination, incorrect labeling, and variable purity are documented concerns with products manufactured outside pharmaceutical-grade standards. There is no legal pathway to obtain melanotan II for cosmetic tanning in the United States as of April 2026. The FDA has not approved melanotan II for any use — cosmetic or therapeutic — and has instead issued public health warnings against its use. There is no regulatory pathway under current FDA policy to obtain cosmetic-use dosing for melanotan II, and no compounding pharmacy can legally supply it for this purpose under current regulations. Melanotan II appears on FDA's list of bulk drug substances nominated but withdrawn, meaning nominations for inclusion on the 503A bulks list were withdrawn and it does not have a lawful compounding pathway under Section 503A for human use.

The FDA has issued public health warnings regarding melanotan products, cautioning consumers against purchasing and using these unapproved injectable peptides. As of April 2026, melanotan II is on FDA's published list of withdrawn-nomination bulk drug substances — meaning it does not have a lawful pathway for compounding for human use by 503A pharmacies. This aligns with FDA's longstanding position that melanotan II is an unapproved new drug with documented safety signals.

FDA-approved afamelanotide (not cosmetic tanning)

Afamelanotide is FDA-approved as Scenesse for erythropoietic protoporphyria, a rare inherited condition causing severe photosensitivity. In this approved indication, it is administered as a subcutaneous implant by a licensed healthcare provider in a clinical setting. Its approval for this specific indication — reviewed and documented by the FDA — is distinct from any cosmetic use and does not provide a legal or clinical basis for grey-market cosmetic tanning products bearing the same or similar compound names. The distinction between FDA/EMA-reviewed melanotropic therapies and unlicensed grey-market versions was covered in a 2013 review in the Journal of Drugs in Dermatology on melanocyte-stimulating hormone therapy including afamelanotide.

Safety Considerations

The safety considerations for tanning peptides are more fully characterized than their efficacy profile. The adverse effects are documented across multiple evidence types, and the mechanisms underlying them are well-understood at the cell biology level.

Known adverse effects

Documented adverse effects of melanotan II include:

• Melanoma: Associated in case reports; mechanism supported by melanocyte proliferation biology [case reports]
• New and changing nevi: Documented in the 2013 Irish Medical Journal case report [case report]
• Hypotension: Documented in the Clinical Toxicology 2012 case report of systemic toxicity [case report]
• Rhabdomyolysis: Documented in the Clinical Toxicology 2012 case report [case report]
• Nausea: Reported in both Phase I studies and user surveys [human study; human observational]
• Facial flushing: Documented in Phase I studies [human study]
• Spontaneous erections: Result of MC4R activation; documented in Phase I studies and extensively in user reports [human study]

Populations who should exercise caution

• Individuals with dysplastic nevi or family history of melanoma: MC1R stimulation in individuals with atypical nevi may drive malignant change. The 2012 melanoma in situ case report specifically involved a patient with dysplastic nevi. A 2019 study in the British Journal of Dermatology showed high nevus count and MC1R red-hair alleles synergistically increase melanoma risk.
• Individuals with MC1R red-hair alleles: This genotype is associated with elevated melanoma risk; MC1R agonism in this population carries theoretical additional concern. The 2019 British Journal of Dermatology study documented this interaction.
• Individuals with active or prior skin cancer: Stimulation of melanocyte proliferation in individuals with a history of melanoma or atypical nevi is contraindicated based on mechanism alone.
• Pregnant or breastfeeding individuals: No reproductive safety data exists for either compound in humans.
• Individuals with cardiovascular conditions: Hypotension is a documented acute adverse effect; individuals with hemodynamic compromise may be at greater risk from this effect.

What is not yet known

Long-term safety data for cosmetic melanotan use does not exist in the peer-reviewed literature. Drug interaction data is not available. The cumulative risk of repeated MC1R stimulation over years — including any additive risk for melanoma in the context of UV exposure — has not been characterized in controlled studies. Reporting and regulatory-agency communications have documented that melanotan II is marketed to consumers online with minimal harm messaging, despite its unlicensed status in the UK, EU, US, and Australia — meaning most consumer-facing information about these compounds does not include the documented safety concerns described above.

What the nuanced risk-benefit picture shows

Böhm and colleagues, in a 2025 review in the Journal of the European Academy of Dermatology and Venereology, reviewed benefits and risks of chronic MC1R activation, noting that while eumelanin offers UV protection, MC1R stimulation does not reliably prevent melanoma in high-risk individuals. The UV protection narrative — sometimes cited to suggest tanning peptides are beneficial — does not extend to melanoma prevention in susceptible populations. Melanin synthesis and cancer protection are not the same outcome, and the research does not support treating them as interchangeable.

Legal Status and Why Tanning Peptides Are Not Available for Cosmetic Use

As of April 2026, there is no legal pathway to obtain melanotan II for cosmetic tanning in the United States. The compound is not FDA-approved for any human use. Products labeled as melanotan II sold through online "research chemical" vendors are not exempt from FDA's new-drug requirements simply because of "research use only" labeling. Under the FDA's intended-use doctrine (21 CFR 201.128), a product's actual intended use — not just its stated label — determines its regulatory status, and melanotan II marketed for human cosmetic tanning is an unapproved new drug regardless of "RUO" labeling. Independent testing has identified contamination, incorrect dosing, and misidentified compounds in peptide products marketed for research use only. Superpower does not prescribe, sell, or facilitate access to melanotan II.

Superpower does not prescribe, sell, compound, distribute, or facilitate access to melanotan I, melanotan II, or any unapproved tanning peptide from any source — including compounding pharmacies, international pharmacies, research-chemical vendors, or online resellers. The absence of a lawful US pathway is not a sourcing challenge to be solved; it reflects FDA's regulatory position on the compound. Individuals encountering these products in any channel should understand they are unapproved new drugs and that use of them is outside FDA's regulatory framework.

Afamelanotide (Scenesse) is legally available in the United States only for erythropoietic protoporphyria, through a licensed healthcare provider, in the FDA-approved product form. There is no OTC or consumer access pathway for afamelanotide. Individuals with erythropoietic protoporphyria interested in this approved therapy should discuss it with a specialist in metabolic disorders or dermatology.

Research into MC1R pharmacology continues at the basic-science level. A 2019 study in the International Journal of Molecular Sciences described a selective MC1R agonist pentapeptide in preclinical skin pigmentation research. Investigational compounds of this type are not approved for any human use, are not available through any legal consumer or clinical pathway, and are not substitutes for sun-avoidance and photoprotection behaviors. Laboratory receptor-selectivity observations in cell or animal models are not evidence of human safety or a legitimate consumer-access pathway. As of April 2026, no MC1R agonist peptide is FDA-approved for cosmetic skin pigmentation, and no pathway for consumer use exists.

Which Biomarkers Are Relevant for Tanning Peptide Safety?

The most relevant surveillance tool for anyone who has used tanning peptides is a dermatological examination, not bloodwork. Dermatoscopic assessment of nevi by a board-certified dermatologist is the standard of care for monitoring melanocytic changes. That said, for individuals managing overall health context following use of any unregulated injectable compound, specific markers provide relevant baseline information.

• Skin and nevus surveillance: Not a blood test, but the primary recommended monitoring tool. Anyone with dysplastic nevi, a family history of melanoma, or a history of melanotan use should discuss skin surveillance frequency with a dermatologist. Bloodwork does not substitute for dermatoscopic assessment by a board-certified dermatologist.
• Inflammatory markers (hs-CRP): A baseline hs-CRP measurement provides systemic inflammatory context for anyone who has used injectable research compounds and wants to understand their current inflammatory baseline.
• Liver enzymes (ALT, AST): Standard safety context for anyone who has used injectable compounds with unknown hepatic processing effects. Liver function baseline is part of standard pre-treatment and post-use assessment in clinical pharmacology contexts.
• Comprehensive metabolic baseline: For anyone seeking a complete picture of their current health status following use of grey-market injectable compounds, a broad metabolic panel covering kidney function, liver function, and inflammatory markers provides objective context. The complete guide to biomarker testing outlines what a baseline panel should include.

Understanding your biological baseline — including inflammatory markers and organ function — is the foundation for any conversation with a healthcare provider about past or current use of unregulated compounds. That principle is central to Superpower's approach to preventive health: objective data is more useful than self-reported experience when the question involves biology you cannot directly observe.

IMPORTANT SAFETY INFORMATION

Melanotan II is not approved by the FDA for any medical use. Research on this compound has documented melanocytic changes, melanoma case reports, and systemic adverse effects in humans. As of April 2026, there is no legal pathway to obtain melanotan II for cosmetic tanning or any other human therapeutic use in the United States. Afamelanotide (Scenesse) is FDA-approved only for erythropoietic protoporphyria — its approval does not extend to cosmetic tanning. Superpower does not prescribe, sell, compound, or facilitate access to melanotan II or any unapproved tanning peptide. This page is provided for educational and informational purposes only and does not constitute medical advice or an endorsement of use.

Do not use melanotan II if you have: a personal or family history of melanoma or atypical nevi; MC1R red-hair alleles or a history of severe sunburn; any active skin cancer; cardiovascular disease or hemodynamic instability; pregnancy or plans to become pregnant (no reproductive safety data exists).

Warnings: Documented adverse effects include nausea, spontaneous erections, facial flushing, hypotension, and new or changing nevi. Case reports associate use with melanoma development. Long-term safety data does not exist. Grey-market products carry documented contamination, incorrect dosing, and misidentification risks. No safe dose for cosmetic use has been established.

Common adverse effects in Phase I studies: nausea, spontaneous erections, facial flushing, hypotension. Real-world additional reports: new nevi, changing existing moles, systemic toxicity. Case reports have associated melanotan II use with melanoma; causation has not been established through controlled trials, and the number of published case reports combined with the mechanistic plausibility represents a documented safety concern warranting serious consideration.

As of April 2026, no completed human safety or efficacy trials for cosmetic tanning use of melanotan I or II have been published. Products sold through unregulated online channels are not subject to pharmaceutical-grade manufacturing standards.

Disclaimer: IMPORTANT: Superpower does not prescribe, sell, or facilitate access to melanotan I, melanotan II, or any unapproved tanning peptide. This page is provided for educational and informational purposes only.